Latest Hotspot

Sandoz introduces Hyrimoz® (adalimumab) high-dose variant in Europe to enhance patient treatment

29 November 2023
3 min read

Sandoz, the worldwide pioneer in generic and biosimilar medication, today publicizes the introduction of Hyrimoz® (adalimumab) without citrate high concentration version in Europe. The medication will gradually become accessible to patients throughout European nations, the process commences today.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

"Living with chronic inflammatory diseases can severely disrupt everyday life," said Rebecca Guntern, Europe President of Sandoz. “The roll out of Hyrimoz® HCF in Europe marks an important step in providing an alternative therapy for those in need, reflecting our ongoing dedication to broadening the availability of high-standard treatments."

Hyrimoz® citrate-free HCF, an improved formulation of the existing Hyrimoz® 50 mg/mL, reduces the injection volume by half, which may lessen the injection frequency for patients requiring an 80 mg/mL or higher dose. The HCF formulation is applied with the familiar Hyrimoz® SensoReady® pen, aiming to optimise the patient experience while keeping it recognisable.

The introduction of Hyrimoz ® HCF fortifies Sandoz's biosimilar selection in the field of immunology, which includes Erelzi® (biosimilar etanercept), Zessly® (biosimilar infliximab), and Rixathon® (biosimilar rituximab, including for the treatment of rheumatoid arthritis). The Hyrimoz® citrate-free HCF debuted in the US market in July 2023.

Dedicated to enabling millions of patients to access vital and possibly life-altering biologic treatments sustainably and economically, Sandoz operates in various fields including immunology, oncology, supportive care, and endocrinology. The company boasts a foremost international portfolio of eight marketed biosimilars, along with 25 additional assets at various developmental stages.

After launching the first European biosimilar in 2006, Sandoz has played a major part in facilitating early and widespread patient access to transformative treatments, leading to considerable healthcare cost savings and driving competition that spurs additional innovations.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of November 28, 2023, there are 306 investigational drugs for the TNF-α target, including 215 indications, 391 R&D institutions involved, with related clinical trials reaching 4320, and as many as 53413 patents.

Adalimumab is a human immunoglobulin G1 monoclonal antibody targeting tumor necrosis factor alpha (TNF-α). The adalimumab reference medicine (Humira®*) was first approved with an adalimumab concentration of 50 mg/mL.1 In 2015, the EMA and US FDA approved Humira® HCF, which contains adalimumab at a concentration of 100 mg/mL.

图形用户界面, 文本, 应用程序

描述已自动生成

Decoding Axicabtagene Ciloleucel: a comprehensive study of its R&D trends and its clinical results in 2023 ASH
Decoding Axicabtagene Ciloleucel: a comprehensive study of its R&D trends and its clinical results in 2023 ASH
29 November 2023
On 11 Dec 2023, The clinical data about Axicabtagene Ciloleucel from pivotal ZUMA-7 study will be updated in 2023 ASH.
Read →
European Commission approves Ascendis Pharma's YORVIPATH® (palopegteriparatide) for treating chronic Hypoparathyroidism in adults
Latest Hotspot
3 min read
European Commission approves Ascendis Pharma's YORVIPATH® (palopegteriparatide) for treating chronic Hypoparathyroidism in adults
29 November 2023
European Commission gives the green light to Ascendis Pharma's YORVIPATH® (palopegteriparatide) for managing chronic Hypoparathyroidism in adults.
Read →
What are KRAS inhibitors and how do you quickly get the latest development progress?
What are KRAS inhibitors and how do you quickly get the latest development progress?
29 November 2023
The KRAS mutation, as a significant driving factor for non-small cell lung cancer, has long been a challenging type of mutation. However, the recent development and clinical application of various KRAS inhibitors have brought us new hope.
Read →
ProMIS Neurosciences begins Phase 1a trial, administering PMN310, a potential Alzheimer's treatment, to initial participants
Latest Hotspot
3 min read
ProMIS Neurosciences begins Phase 1a trial, administering PMN310, a potential Alzheimer's treatment, to initial participants
29 November 2023
ProMIS Neurosciences initiates Phase 1a clinical trial, injecting the first participants with PMN310, a potential Alzheimer’s Disease treatment.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.